Avinger (NSDQ:AVGR) this week released preliminary analysis results from its SCAN post-market study comparing optical coherence (OCT) to intravascular ultrasound (IVUS), touting that data indicated that OCT imaging with its Pantheris system showed statistical superiority or equivalence to IVUS.
In the study, researchers compared 240 matched images, 120 OCT and 120 IVUS, captured at identical positions within vessel segments from 12 subjects at two clinical centers, the Redwood City, Calif.-based company said. The images were reviewed and ranked by three independent radiologists on image quality and their ability to display vessel morphology and disease, Avinger said.
Results from the analysis indicated that OCT imaging with Pantheris was significantly better than IVUS at visualizing plaque, calcification and stent struts, and OCT imaging was ranked to be statistically equivalent to IVUS in visualizing the layered structures of the vessel wall and for visualizing troughs following atherectomy.
Vessel management and artifact interference with image quality were also rated to be statistically equivalent between OCT and IVUS, Avinger said.
“The SCAN study does an excellent job demonstrating the clinical value of intravascular imaging with OCT and IVUS for the diagnosis of peripheral arterial disease. While OCT performed better on certain parameters, what is paramount to providing excellent clinical results is the capability to see what is present in the vessel so that diseased tissue can be removed without causing injury to healthy tissue. To our knowledge, SCAN is only the second study in the world and the first U.S.-based study comparing OCT with IVUS intravascular imaging in the peripheral vessels. We look forward to sharing more detailed findings of the study as they become available,” physician investigator Dr. Edward Pavillard of King of Prussia, Penn.’s PA Vascular Institute said in a press release.
Last month, Avinger said that it closed an approximately $11.5 million round of financing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.